Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application
Open Access
- 1 March 2014
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 48 (2) , 200-207
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- New FDA Regulation to Improve Safety Reporting in Clinical TrialsNew England Journal of Medicine, 2011
- Planning and core analyses for periodic aggregate safety data reviewsClinical Trials, 2011
- Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.2010
- Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamClinical Trials, 2009